文献速递神经肿瘤神经重症

铯-131近距离放疗在脑肿瘤中的作用:文献及在研临床试验的范围综述

The role of cesium-131 brachytherapy in brain tumors: a scoping review of the literature and ongoing clinical trials.
PubMed 文献 · J Neurooncol · 2022-06-13

本范围综述检索了PubMed、Web-of-Science、Scopus、Clinicaltrial.gov和Cochrane数据库,纳入27项已发表研究(279例患者、293个病灶)和3项在研试验,评估铯-131近距离放疗在脑肿瘤中的应用。多数患者为脑转移瘤(63.1%),其次为高级别胶质瘤(23.3%)和脑膜瘤(13.6%)。初步数据提示铯-131近距离放疗在原发或转移性恶性脑肿瘤中安全有效,在研试验正在评估长期局部区域肿瘤控制。

要点

  • 纳入27项研究共279例患者293个病灶,另3项在研试验。
  • 脑转移瘤占63.1%,高级别胶质瘤占23.3%,脑膜瘤占13.6%。
  • 1年无进展率:局部94%,区域85.1%,远处53.5%。

核心结论

  • 初步数据提示铯-131近距离放疗在原发或转移性恶性脑肿瘤中安全有效。
  • 在研试验正在评估长期局部区域肿瘤控制,未来研究应分析其在多模式全身肿瘤管理中的作用。

研究设计与样本

  • 范围综述,检索PubMed、Web-of-Science、Scopus、Clinicaltrial.gov和Cochrane数据库,遵循PRISMA范围综述扩展版。
  • 纳入已发表研究和在研试验,共27项已发表研究(279例患者、293个病灶)和3项在研试验。

主要发现

  • 多数患者为脑转移瘤(63.1%),其次为高级别胶质瘤(23.3%)和脑膜瘤(13.6%)。
  • 高级别胶质瘤中WHO III级占15.2%、IV级占84.8%;脑膜瘤中WHO II级占62.8%、III级占27.9%。
  • 多数脑转移瘤为新诊断(72.3%),多数胶质瘤和脑膜瘤为复发(分别为95.4%和88.4%)。
  • 患者接受全切除(91.1%)或次全切除(8.9%),术后腔中位大小为3.5 cm(范围1-5.8 cm)。
  • 胶质瘤、脑膜瘤和脑转移瘤中位植入种子数分别为20、28和16枚,中位种子活度为3.8 mCi(范围2.4-5 mCi)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Cesium-131 radioactive isotope has favored the resurgence of intracavitary brachytherapy in neuro-oncology, minimizing radiation-induced complications and maximizing logistical and clinical outcomes. We reviewed the literature on cesium-131 brachytherapy for brain tumors. METHODS: PubMed, Web-of-Science, Scopus, Clinicaltrial.gov, and Cochrane were searched following the PRISMA extension for scoping reviews to include published studies and ongoing trials reporting cesium-131 brachytherapy for brain tumors. RESULTS: We included 27 published studies comprising 279 patients with 293 lesions, and 3 ongoing trials. Most patients had brain metastases (63.1%), followed by high-grade gliomas (23.3%), of WHO Grade III (15.2%) and Grade IV (84.8%), and meningiomas (13.6%), mostly of WHO Grade II (62.8%) and Grade III (27.9%). Most brain metastases were newly diagnosed (72.3%), while most gliomas and meningiomas were recurrent (95.4% and 88.4%). Patients underwent gross-total (91.1%) or subtotal (8.9%) resection, with median postoperative cavity size of 3.5 cm (range 1-5.8 cm). A median of 20, 28, and 16 seeds were implanted in gliomas, meningiomas, and brain metastases, with median seed activity of 3.8 mCi (range 2.4-5 mCi). Median follow-up was 16.2 months (range 0.6-72 months). 1-year freedom from progression rates were local 94% (range 57-100%), regional 85.1% (range 55.6-93.8%), and distant 53.5% (range 26.3-67.4%). Post-treatment radiation necrosis, seizure, and surgical wound infection occurred in 3.4%, 4.7%, and 4.3% patients. CONCLUSION: Initial data suggest that cesium-131 brachytherapy is safe and effective in primary or metastatic malignant brain tumors. Ongoing trials are evaluating long-term locoregional tumor control and future studies should analyze its role in multimodal systemic tumor management.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Palmisciano P, Haider AS, Balasubramanian K, et al. The role of cesium-131 brachytherapy in brain tumors: a scoping review of the literature and ongoing clinical trials. J Neurooncol. 2022. PMID: 35696019. doi:10.1007/s11060-022-04050-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。